Opendata, web and dolomites

PICSOHF SIGNED

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICSOHF project word cloud

Explore the words cloud of the PICSOHF project. It provides you a very rough idea of what is the project "PICSOHF" about.

progressive    66m    improvements    cardiac    follow    stop    patented    patient    pattern    burden    launch    function    recovery    therapy    discredited    solutions    partial    quality    ed    market    profits    attack    co    technological    prognosis    treatments    versus    software    met    continuous    expectations    breakthrough    regenerate    frequent    proof    tissue    intervention    therapies    changed    changing    sustainability    strategic    hope    survival    right    impoverished    commercial    biomarkers    full    healthcare    last    medium    acute    efficacy    despite    feedback    miracor    veins    million    scientific    morbidities    treating    tested    chronic    regeneration    people    catheter    controls    hospitalisations    treatment    22    once    worldwide    significantly    26    temporarily    life    myocardial    device    europe    clinically    reactivating    national    unable    patients    threatens    minutes    demonstrated    hf    regenerative    regain    elevates    clinical    picsohf    cellular    percutaneous    pressure    consists    reference    heart    expectancy    greatest    damaged    live    picso    re    innate    proprietary   

Project "PICSOHF" data sheet

The following table provides information about the project.

Coordinator
MIRACOR MEDICAL 

Organization address
address: RUE DE BRUXELLES 174, E40 BUSINESS
city: AWANS
postcode: 4340
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIRACOR MEDICAL BE (AWANS) coordinator 50˙000.00

Map

 Project objective

Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations. Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy. Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up. Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by €66M within 5 years after commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICSOHF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICSOHF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

TankSensor (2020)

Smart monitoring solution for better procurement and supply chain management - Speeding up chemical industry digitalization

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More